Difficulty: Medium
Average Score: 93%
Practice
Combined therapy with dipyridamole and warfarin is recommended in subjects with the following
Correct answer
D
Rationale
In clinical practice, the combination of dipyridamole and warfarin is recommended in individuals with prosthetic heart valves and chronic arteriovenous shunts for repeated hemodialysis. The correct answer, option D, encompasses both these conditions.
Prosthetic heart valves are associated with a higher risk of thromboembolism, and warfarin is commonly prescribed to prevent clot formation. Dipyridamole, on the other hand, acts as a platelet aggregation inhibitor and enhances the effects of anticoagulants like warfarin, providing added protection against clot formation in patients with prosthetic heart valves.
Chronic arteriovenous shunts for repeated hemodialysis also increase the risk of clot formation due to the artificial connection between artery and vein. This setting requires anticoagulation therapy to prevent clotting within the shunt. The combination of dipyridamole and warfarin can be beneficial in such cases to provide dual protection against thrombosis.
Option A, risk factors for coronary artery disease, is not specifically indicative of the need for combined therapy with dipyridamole and warfarin. While these individuals may benefit from cardiovascular pharmacotherapy, it does not specifically warrant the combination mentioned in the question.
Option C, chronic arteriovenous shunts for repeated hemodialysis, is partly correct as it addresses one of the conditions requiring the combined therapy. However, it fails to include prosthetic heart valves, which are also a crucial indication for this specific drug combination.
Understanding the rationale behind the recommended combination therapy in these clinical scenarios is essential for healthcare professionals managing patients with cardiovascular conditions. It highlights the importance of tailoring pharmacological interventions based on individual patient characteristics and disease states to optimize treatment outcomes and minimize risks.
Prosthetic heart valves are associated with a higher risk of thromboembolism, and warfarin is commonly prescribed to prevent clot formation. Dipyridamole, on the other hand, acts as a platelet aggregation inhibitor and enhances the effects of anticoagulants like warfarin, providing added protection against clot formation in patients with prosthetic heart valves.
Chronic arteriovenous shunts for repeated hemodialysis also increase the risk of clot formation due to the artificial connection between artery and vein. This setting requires anticoagulation therapy to prevent clotting within the shunt. The combination of dipyridamole and warfarin can be beneficial in such cases to provide dual protection against thrombosis.
Option A, risk factors for coronary artery disease, is not specifically indicative of the need for combined therapy with dipyridamole and warfarin. While these individuals may benefit from cardiovascular pharmacotherapy, it does not specifically warrant the combination mentioned in the question.
Option C, chronic arteriovenous shunts for repeated hemodialysis, is partly correct as it addresses one of the conditions requiring the combined therapy. However, it fails to include prosthetic heart valves, which are also a crucial indication for this specific drug combination.
Understanding the rationale behind the recommended combination therapy in these clinical scenarios is essential for healthcare professionals managing patients with cardiovascular conditions. It highlights the importance of tailoring pharmacological interventions based on individual patient characteristics and disease states to optimize treatment outcomes and minimize risks.